INERIS, France
Biography:
Benedicte Trouiller has completed her Postdoctoral Studies from University of California, Los Angeles, USA. She is currently working as a Researcher of INERIS. She has published more than 25 papers in reputed journals and has been serving as an editorial board member of repute.
Titanium dioxide (TiO2) nanoparticles (NPs) can cause negative health effects such as respiratory tract cancer in rats. However, mechanisms involved in TiO2 NP-induced carcinogenicity have not been clearly defined and are yet poorly studied in vivo. The present study compared genotoxicity (DNA lesions with the comet assay and chromosomal damages with the micronucleus assay), oxidative stress (glutathione content) and inflammation (LBA numeration and cytokines) in rats exposed to 2 TiO2 NPs (NM105: P25, 23 nm, 85% anatase / 15% rutile, 46 m²/g; and NM101: Hombikat UV100, 7 nm, anatase, 300 m²/g) in 3 instillations at a 4-days interval accounting for total final doses of 0.5, 2.5 and 10 mg/ kg spread over 12 days. Endpoints were assessed at two time points, 2 hours and 35 days after the last instillation. This study confirmed two lung overload thresholds, previously described.
INERIS, France
Biography:
Benedicte Trouiller has completed her Postdoctoral Studies from University of California, Los Angeles, USA. She is currently working as a Researcher of INERIS. She has published more than 25 papers in reputed journals and has been serving as an editorial board member of repute.
Titanium dioxide (TiO2) nanoparticles (NPs) can cause negative health effects such as respiratory tract cancer in rats. However, mechanisms involved in TiO2 NP-induced carcinogenicity have not been clearly defined and are yet poorly studied in vivo. The present study compared genotoxicity (DNA lesions with the comet assay and chromosomal damages with the micronucleus assay), oxidative stress (glutathione content) and inflammation (LBA numeration and cytokines) in rats exposed to 2 TiO2 NPs (NM105: P25, 23 nm, 85% anatase / 15% rutile, 46 m²/g; and NM101: Hombikat UV100, 7 nm, anatase, 300 m²/g) in 3 instillations at a 4-days interval accounting for total final doses of 0.5, 2.5 and 10 mg/ kg spread over 12 days. Endpoints were assessed at two time points, 2 hours and 35 days after the last instillation. This study confirmed two lung overload thresholds, previously described.